{"id":"NCT05566639","sponsor":"ModernaTX, Inc.","briefTitle":"A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older","officialTitle":"A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-09-14","primaryCompletion":"2024-01-05","completion":"2024-01-05","firstPosted":"2022-10-04","resultsPosted":"2025-01-16","lastUpdate":"2025-01-16"},"enrollment":22502,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Seasonal Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"mRNA-1010","otherNames":["Seasonal influenza vaccine"]},{"type":"BIOLOGICAL","name":"Fluarix Quadrivalent","otherNames":["Licensed quadrivalent inactivated seasonal influenza vaccine"]}],"arms":[{"label":"mRNA-1010","type":"EXPERIMENTAL"},{"label":"Fluarix Quadrivalent","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of mRNA-1010 in preventing seasonal influenza in adults 50 years and older.","primaryOutcome":{"measure":"Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)","timeFrame":"7 days post-vaccination","effectByArm":[{"arm":"Fluarix Quadrivalent","deltaMin":5620,"sd":null},{"arm":"mRNA-1010","deltaMin":7989,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":12},"locations":{"siteCount":233,"countries":["United States","Bulgaria","Canada","Denmark","Estonia","Germany","Netherlands","Poland","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":495,"n":11200},"commonTop":["COVID-19"]}}